Literature DB >> 23721951

Prevalence and associated metabolic factors of fatty liver disease in the elderly.

Zhongli Wang1, Ming Xu, Jianhong Peng, Li Jiang, Zhengguo Hu, Hua Wang, Shiqing Zhou, Rui Zhou, Michael Hultström, En Yin Lai.   

Abstract

OBJECTIVE: The aim of this study was to investigate the metabolic risk factors for fatty liver disease in the elderly, and determine the prevalence of fatty liver disease in the elderly in Wuhan, central China.
METHODS: The study was a case-control study based on all 4226 adults above 60 years of age from a cohort investigated in 2010-11 at the medical examination center of Zhongnan hospital, using 3145 randomly selected adults under 60 years of age from the same cohort as controls. Fatty liver disease (FLD) was identified with ultrasound imaging. The risk factors measured were body mass index (BMI), and plasma concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low density lipoprotein (LDL) and serum uric acid (SUA). The probability of steatohepatitis with advanced fibrosis was predicted using a score based on BMI, age, ALT, and TG (BAAT),and using AST/ALT ratio (AAR).
RESULTS: FLD was higher in the elderly (26.7%) than in the non-elderly (22.8%) and similar in the elderly between men and women (26.6% vs 27.0%, p>0.05). BMI, TC, TG, LDL, SUA, AST and ALT were all significantly higher in FLD, whereas the level of HDL was markedly lower. Multiple regression analyses showed that obesity, high TC, TG, SUA, low HDL, and elevated ALT, AAR<1 were closely related to the elderly FLD, while male sex, obesity, high TC, TG, low HDL, elevated ALT, AST and AAR<1 were closely related to the non-elderly FLD. The prevalence of steatohepatitis with advanced fibrosis estimated as BAAT index≥3 was 2.4% in all subjects, and was higher in the elderly FLD patients than in the non-elderly FLD patients.
CONCLUSION: The prevalence of FLD is higher in the elderly, and is broadly related to the same metabolic risk factors as in the non-elderly. However, female-sex is no longer protective with increasing age, and the prevalence of steatohepatitis with advanced fibrosis is estimated to be considerably higher in the elderly FLD patients than in the non-elderly FLD controls.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAR; ALT; AST; Advanced fibrosis; BAAT; Elderly; FLD; Fatty liver; HDL; LDL; MS; NAFLD; NASH; Prevalence; Risk factors; SUA; TC; TG; alanine aminotransferase; aspartate aminotransferase; aspartate aminotransferase/alanine aminotransferase ratio; body mass index, age, ALT, and triglyceride score; fatty liver disease; high-density lipoprotein; low-density lipoprotein; metabolic syndrome; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; serum uric acid; total cholesterol; triglyceride

Mesh:

Substances:

Year:  2013        PMID: 23721951     DOI: 10.1016/j.exger.2013.05.059

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  23 in total

1.  The prevalence and adverse profiles of fatty liver disease among different ethnic public servants in Urumqi of Xinjiang Uygur Autonomous Region in China.

Authors:  Dan Chen; Jie Guan; Xiang Xie; Wei-Yun Zhao; Palida Abulaiti; Yu Wang; Zhi-Qin Cheng; Jing Zhang; Ying Gao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.

Authors:  Zhen-Ya Lu; Zhou Shao; Ya-Li Li; Muhuyati Wulasihan; Xin-Hua Chen
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

Review 3.  Role of diet on non-alcoholic fatty liver disease: An updated narrative review.

Authors:  Dimitrios Papandreou; Eleni Andreou
Journal:  World J Hepatol       Date:  2015-03-27

4.  Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients.

Authors:  Gabriela Paredes-Turrubiarte; Antonio González-Chávez; Ruy Pérez-Tamayo; Beatriz Y Salazar-Vázquez; Vito S Hernández; Nayeli Garibay-Nieto; José Manuel Fragoso; Galileo Escobedo
Journal:  Clin Exp Med       Date:  2015-04-18       Impact factor: 3.984

Review 5.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

6.  Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease.

Authors:  George Boon-Bee Goh; Mangesh R Pagadala; Jaividhya Dasarathy; Aynur Unalp-Arida; Rish K Pai; Lisa Yerian; Amer Khiyami; Achuthan Sourianarayanane; Ruth Sargent; Carol Hawkins; Srinivasan Dasarathy; Arthur J McCullough
Journal:  Dig Dis Sci       Date:  2015-02-24       Impact factor: 3.199

7.  Effect of nuclear factor-κB and angiotensin II receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease.

Authors:  Dao-Yu Tan; Hai-Yan Shi; Chang-Ping Li; Xiao-Ling Zhong; Ming Kang
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

8.  Study on the protective mechanism of dexmedetomidine on the liver of perioperative diabetic patients: A randomized controlled trial.

Authors:  Lin Zeng; Juan Liu; Tianyao Zhang; Yusong Liu; Lumiu Liao; Xuelian Chen; Shuhua Dong
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

Review 9.  Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease.

Authors:  Zobair M Younossi; Linda Henry
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

Review 10.  Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back.

Authors:  Chengfu Xu
Journal:  Hepatol Int       Date:  2015-12-15       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.